COVINGTON, Ky., Oct. 10,
2023 /PRNewswire/ -- Bexion Pharmaceuticals, Inc., a
clinical-stage biopharmaceutical company developing a new
generation of biologic therapy to treat solid tumor cancers and
chemotherapy-induced peripheral neuropathy (CIPN), today announced
the appointment of Dr. Catherine
Pearce, DHSc, MBA, to the Company's Board of Directors,
effective October 1, 2023.
Dr. Pearce is a seasoned biopharmaceutical executive with 25
years of drug development, corporate development and C-Suite
experience. Dr. Pearce led hundreds of global clinical trials at
Medpace, where she later built out business development and
marketing teams. At Teva Pharmaceuticals, Dr. Pearce evaluated
generics for repurposing, leading to the approval of Uzedy for the
treatment of schizophrenia. Dr. Pearce later co-founded CinRx, a
biotech incubator, which developed 6 portfolio companies including
CinCor, which was acquired by AstraZeneca in February 2023. Additionally, Dr. Pearce is the
founder and CEO of JucaBio and is a member of the Board of Trustees
of Xavier University and an Advisor to
several start-ups. Dr. Pearce holds a BS and MBA from Xavier University, and a Doctorate of Health
Sciences (DHSc) from Nova Southeastern
University.
Scott Shively, CEO and President
of Bexion Pharmaceuticals, commented, "As Bexion enters the next
stage of our growth and progresses our clinical development program
for BXQ-350, we are excited to welcome Catherine as a key member of
our Board. She has deep experience shepherding drugs through
clinical development, successfully closing transactions and has
been a leader in biotechnology companies across multiple stages of
development. Catherine will be a fantastic asset to us as we
continue to progress the company".
Catherine Pearce, DHSc, MBA,
stated, "I am excited to be joining Bexion at this critical
inflection point in their development of BXQ-350. Helping to bring
this promising medicine forward to patients as efficiently as
possible is a great opportunity."
Bexion was founded based on technology that was invented at
Cincinnati Children's Hospital & Medical Center. The health
system, which licensed the technology to Bexion, stated: "Catherine
is an accomplished biotech leader in both Cincinnati and the industry at large. We are
proud to have her represent Cincinnati Children's as part
of Bexion's Board."
About Bexion Pharmaceuticals
Bexion Pharmaceuticals, a
clinical-stage biopharmaceutical company, is developing a new
generation of biologic therapy to treat solid tumor cancers and
chemotherapy-induced peripheral neuropathy (CIPN) with potential
portfolio expansion opportunities in other cancers and broader
neuropathic pain indications. Bexion currently has three clinical
trials open for enrollment.
Investor Contact:
William
Windham
Solebury Strategic Communications
646-378-2946
wwindham@soleburystrat.com
Media Contact:
Joyce
LaViscount
Bexion Pharmaceuticals
859-446-7386
jlaviscount@bexionpharma.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/bexion-pharmaceuticals-inc-appoints-dr-catherine-pearce-dhsc-mba-to-board-of-directors-301952712.html
SOURCE Bexion Pharmaceuticals, Inc.